Table 3. Immunostaining of all analysed proteins in BPH and prostate tumour samples.
|
IHC positive staining (%) (n positive/n total)
|
||||||
|---|---|---|---|---|---|---|
| No. of cases (n) | MYCa | BARK1a | PP1αa | FASNa | NM23-H1b | PP2Aa,b |
| Tumour (n=131) | 52% | 93% | 71% | 54% | 59% | 54% |
| BPH (n=126) | 78% | 92% | 56% | 15% | 61% | 56% |
| P-value | <0.001 | 0.807 | 0.020 | <0.001 | 0.685 | 0.891 |
| Adjusted P-valuec | <0.001 | 1.000 | 0.120 | <0.001 | 1.000 | 1.000 |
BARK1=β-adrenergic receptor kinase 1; FASN=Fatty acid synthase; PP2A=protein phosphatases.
a
Cytoplasmic immunostaining.
b
Nuclear immunostaining.
c
In order to correct for multiple testing P-values were adjusted using Bonferroni–Holm correction.